최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Communications for statistical applications and methods = 한국통계학회논문집, v.22 no.4, 2015년, pp.389 - 399
Kang, Seung-Ho (Department of Applied Statistics, Yonsei University) , Jung, Ji-Yong (Department of Applied Statistics, Yonsei University) , Baik, Seon-Hye (Department of Applied Statistics, Yonsei University)
It is important not to overcalculate sample sizes for clinical trials due to economic, ethical, and scientific reasons. Kang and Kim (2014) investigated the accuracy of a well-known sample size calculation formula based on the approximate power for continuous endpoints in equivalence trials, which h...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Altman, D. G. (1980). Statistics and ethics in medical research, III: How large a sample? The British Medical Journal, 281, 1336-1338.
Chow, S. C. (2014). Biosimilars: Design and Analysis of Follow-on Biologics, CRC Press, Boca Raton, Florida.
Chow, S. C., Hsieh, T. C., Chi, E. and Yang J. (2009). A comparison of moment-based and probabilitybased criteria for assessment of follow-on biologics, Journal of Biopharmaceutical Statistics, 20, 31-45.
Chow, S. C. and Liu, J. P. (2010). Statistical assessment of biosimilar products, Journal of Biopharmaceutical Statistics, 20, 10-30.
Chow, S. C., Shao, J. and Wang, H. (2003). Sample Size Calculations in Clinical Research, Marcel Dekker, New York.
Chow, S. C., Wang, J., Endrenyi, L. and Lachenbruch, P. A. (2013). Scientific considerations for assessing biosimilar products, Statistics in Medicine, 32, 370-381.
Hsieh, T. C., Chow, S. C., Yang, L. Y. and Chi, E. (2013). The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics, Statistics in Medicine, 32, 406-414.
Kang, S. H. and Chow, S. C. (2013). Statistical assessment of biosimilarity based on relative distance between follow-on biologics, Statistics in Medicine, 32, 382-392.
Kang, S. H. and Kim, Y. (2014). Sample size calculations for the development of biosimilar products. Journal of Biopharmaceutical Statistics, 24, 1215-1224.
Li, Y., Liu, Q., Wood, P. and Johri, A. (2013). Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins, Statistics in Medicine, 32, 393-405.
Moher, D., Dulberg, C. S. and Wells, G. A. (1994). Statistical power, sample size, and their reporting in randomized controlled trials, Journal of the American Medical Association, 272, 122-124.
Sinclair, J. C. and Bracken, M. B. (1994). Clinically useful measures of effect in binary analyses of randomized trials, Journal of Clinical Epidemiology, 47, 881-889.
US Food and Drug Administration (2012). Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, US Food and Drug Administration, Rockville, MD.
Walter, S. D. (2000). Choice of effect measure for epidemiological data, Journal of Clinical Epidemiology, 53, 931-939.
Wang, H., Chow, S. C. and Li, G. (2002). On sample size calculation based on odds ratio in clinical trials, Journal of Biopharmaceutical Statistics, 12, 471-483.
World Health Organization (2009). Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), World Health Organization, Geneva.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.